top of page
How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex with Dr. Tyler Sandow, Dr. Sabeen Dhand, Dr. Zach Berman, Dr. Kirema Garcia-Reyes, Dr. Siddharth Padia on the BackTable VI Podcast
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Vascular & Interventional

Episode # 511  •  24 Jan 2025

How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex

Of all the topics covered during interventional radiology training, dosimetry education is often delayed until after IRs enter clinical practice. In this episode, Drs. Tyler Sandow and Sabeen Dhand host a roundtable discussion with experts on the dosimetry fundamentals that all Y90 operators should understand. They are joined by interventional radiologists Drs. Zachary Berman, Kirema Garcia-Reyes, and Siddharth Padia, who provide their expert insights.

This podcast is supported by an educational grant from AstraZeneca Pharmaceuticals and Boston Scientific.

Timestamps

00:00 - Introduction
01:59 - Dosimetry Education During Training
05:46 - Benefit of Individualized Dosing
11:01 - Complications from High Doses
15:19 - Dosage Calculation Cases
22:51 - Duration of Response to Y90
25:00 - Dosing Based on Treatment Intent
29:11 - Challenging Case Example
42:31 - Voxel-Based Dosimetry
45:15 - Using Dosimetry Software

Resources

You may also like

See more of the content that's relevant to your practice.

More about this episode

The group agrees that dosimetry is not a one-size-fits-all approach. Dosing strategies depend on factors such as tumor size, perfusion territory, underlying liver function, the choice between glass versus resin spheres, and treatment intent. These considerations are illustrated with real-life case examples. The doctors also explore voxel-based dosimetry, a method for calculating the amount of radiation absorbed by different parts of the tumor. They stress the importance of learning how to perform accurate dosage calculations.

Finally, the conversation touches on data from major Y90 trials, current guidelines, and the evolving perspective on Y90 as a potential curative treatment, rather than merely a bridging therapy.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page